Bernhoven rating affirmed at BBB+ as Fitch cites stable finances

Bernhoven rating affirmed at BBB+ as Fitch cites stable finances
Bernhoven's BBB+ affirmed

Dutch hospital operator Bernhoven keeps its investment-grade ratings after a review of its preliminary 2025 results and sustainability plan. The affirmation leaves the group's long-term issuer ratings at 'BBB+' with a Stable Outlook and highlights continued pressure from rising leverage over the coming five years.

Highlights

  • Fitch affirmed Bernhoven B.V.'s Long-Term IDRs at 'BBB+' with Stable Outlook and Short-Term ratings at 'F2', citing stable finances and limited state support.
  • Bernhoven's 2025 profit rose to EUR7.0 million from EUR4.8 million in 2024, while debt dropped to EUR81.4 million after EUR8.5 million in repayments.
  • Bernhoven remains the weakest-rated Dutch healthcare issuer at 'BBB+', two notches below Stichting Groene Hart Ziekenhuis and Stichting Alrijne Zorggroep, both rated 'A'.

Rating rationale and financial position

As reported by Fitch Ratings, the agency has affirmed Bernhoven B.V.'s Long-Term Foreign- and Local-Currency Issuer Default Ratings at 'BBB+' with Stable Outlooks, and its Short-Term Foreign- and Local-Currency ratings at 'F2'. Fitch says the decision reflects Bernhoven's stable financial position and its assessment of the hospital as a government-related entity of the Netherlands, with no uplift above its standalone credit profile.

Fitch assesses Bernhoven's standalone credit profile at 'bbb+' under its public policy revenue-supported entities criteria. The agency says the hospital receives a support score of five points out of 60 under its government-related entities framework, leading to a standalone approach because expectations of extraordinary state support are viewed as virtually absent.

Bernhoven reported a EUR7.0 million profit in 2025, up from EUR4.8 million in 2024, while total debt fell to EUR81.4 million from EUR89.9 million after EUR8.5 million of repayments. Fitch expects net adjusted debt to EBITDA to stand at 2.6x at end-2025, but to rise above 8x by the end of its rating case, keeping the financial profile at the upper end of the 'bbb' category.

Healthcare market role and sector implications

Fitch says Bernhoven's risk profile is supported by steady healthcare demand, funding ties with insurers and a strong local market position in Uden, where it is the only hospital and serves about 290,000 residents. Revenue from insurers accounts for more than 95% of operating revenue, and the agency expects demand for healthcare and emergency services to keep growing because of an ageing population.

On costs, Fitch says expenditure remains relatively rigid because staffing represents 60% of operating expenses, even as Bernhoven works to reduce reliance on non-salaried staff. Average staffing rose to 1,525 full-time equivalents in 2025 from 1,459 in 2024, mainly due to added project capacity, while wage increases under the current sector labor agreement continue to put pressure on operating costs.

The agency also notes that Bernhoven's liabilities and liquidity profile remains stronger than other parts of its credit assessment, supported by multiple long-term loan facilities and an undrawn EUR15 million committed credit line. Even so, Fitch says Bernhoven remains the weakest-rated issuer among the rated Dutch healthcare entities it compares, with peers Stichting Groene Hart Ziekenhuis and Stichting Alrijne Zorggroep both rated 'A', two notches higher.

We have previously detailed Fitch ratings for RBC Municipal Trust certificates backed by California health facility bonds and RBC credit support.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.